PMS2

A record 31 scientific presentations and posters at the 2024 European Society for Human Genetics (ESHG) Annual Conference and 8 scientific presentations and posters at the 2024 American Cytogenomics Conference (ACC) will highlight the application of optical genome mapping (OGM) in genetic disorder, rare disease, and cancer research applicationsBionano will host a sponsored session at ESHG featuring an overview of the Company’s OGM workflow delivered by Bionano’s chief medical officer, Dr. Alka Chaubey, a presentation from Dr. Laura Batlle Masó at Vall d’Hebron Institute of Research (Spain) on OGM’s potential utility in resolving hereditary angioedema (HAE) cases, a presentation from Dr. Bart van der Sanden at Radboud UMC (Netherlands) on how OGM may be useful for the detection of structural variants (SVs) relevant to rare disease, and a presentation from Marlene Ek at Karolinska Institute (Sweden) highlighting OGM’s ability to unveil more cytogenomic insights into multiple myeloma samples than traditional cytogenetic methods At ACC, a sponsored session will feature Dr. Mike Gallagher, market development manager at Bionano, highlighting OGM’s ability to enhance detection of pathogenic variants and to advance genetic disease research. Dr. Gallagher will also introduce the latest innovations in the OGM workflow, including the Stratys™ system and VIA™ software SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the Company’s robust participation at two upcoming cytogenetics conferences, the 2024 European Society for Human Genetics (ESHG) Annual Conference and the 2024 American Cytogenomics Conference (ACC), with a record 39 scientific presentations and posters across the two conferences that highlight the utility of the Company’s OGM workflow for applications in genetic disease, cancer, and rare disease research and discussing the latest advances to the Company’s suite of products, including the high throughput Stratys system and VIA software. ESHG brings together industry and academic professionals annually to discuss new technologies and advances in the field of human genetics. ESHG sessions will take place June 1-4, 2024 virtually and in Berlin, Germany. ACC is a biennial conference focused on new technologies and advances in the field of cytogenetics. ACC will be held June 2-5, 2024 in Norfolk, Virginia. Bionano will host a sponsored session at ESHG featuring an overview of the Company’s OGM workflow delivered by Bionano’s chief medical officer, Dr. Alka Chaubey, a presentation from Dr. Laura Batlle Masó at Vall d’Hebron Institute of Research (Spain) on OGM’s potential utility in resolving hereditary angioedema (HAE) cases, a presentation from Dr. Bart van der Sanden at Radboud UMC (Netherlands) covering how OGM may be useful for the detection of SVs relevant to rare disease, and a presentation from Marlene Ek at Karolinska Institute (Sweden) highlighting OGM’s ability to unveil more cytogenomic insights into multiple myeloma samples than traditional cytogenetic methods. At ACC, a sponsored session will feature Dr. Mike Gallagher, market development manager at Bionano, highlighting OGM’s ability to enhance detection of pathogenic variants and to advance genetic disease research. Dr. Gallagher will also introduce the latest innovations in the OGM workflow, including the Stratys system and VIA software. Erik Holmlin, PhD, president and chief executive officer of Bionano, stated, “We are excited to see the progress that the global OGM community is making, which is highlighted by the growth in the number of scientific posters and presentations on OGM from the last time the ESHG and ACC conferences were held. We believe this expansion demonstrates the increased customer adoption of OGM, with routine and repeated utilization for innovative research into genetic disorders, cancer and rare disease.” ESHG scientific presentations and poster sessions: Scientific presentations and poster sessions on OGM at ESHG take place in the exhibition halls unless otherwise noted. Abstract/ Poster NumberTitleAuthorsPresentedP14.015.ADeciphering a complex short size RERE rearrangement: importance of combined approaches for duplication interpretationFauqueux J.June 2, 202410:15-11:15 AM CESTP01.065.AA Canadian lab’s experience using optical genome mapping to clinically genotype hematological neoplasmsHamadeh Z.June 2, 202410:15-11:15 AM CESTP03.025.ACharacterization of a complex rearrangement between three chromosomes in a fetus with skeletal anomalies by optical genome mappingHeinrich U.June 2, 202410:15-11:15 AM CESTP16.077.AAccurate identification of pathogenic structural variants guided by multi-platform comparisonMoeinzadeh M.June 2, 202410:15-11:15 CESTP01.163.BDeciphering the molecular complexity of the IKZF1 plus profile using optical genome mappingLühmann J.June 2, 202416:45-17:45 PM CESTP12.023.BSORD and SORD2P inversion: long read sequencing identifies a novel genetic mechanism underlying inherited neuropathyManini A.June 2, 202416:45-17:45 PM CESTP04.029.BOptical genome mapping facilitates rapid characterization of structural variants in families with developmental eye anomaliesMerepa S.June 2, 202416:45-17:45 PM CESTP01.007.CLarge genomic rearrangement: tandem duplication and triplication in BRCA1 gene causative for hereditary breast and ovarian cancerAldrige Allister B.June 3, 202410:15-11:15 AM CESTP15.102.CEstablishing ultra-rapid genome sequencing in neonatal and pediatric intensive care units in Germany – project Baby LionAuber B.June 3, 202410:15-11:15 AM CESTP14.029.COptical genome mapping of a patient with ring chromosome 3 shows the importance of choosing the proper reference genome for the analysisBurssed B.June 3, 202410:15-11:15 AM CESTP14.025.CPositive predictive value of balanced structural variants reported through short-read genome sequencing: do we need orthogonal confirmation?Chatron N.June 3, 202410:15-11:15 AM CESTP14.013.COptical genome mapping identifies hidden structural variants in 58 undiagnosed rare disease patient-parent triosHoischen A.June 3, 202410:15-11:15 AM CESTP01.160.CDeciphering copy number variations within the complex genomic region of the PMS2 gene using optical genome mappingMaier J.June 3, 202410:15-11:15 AM CESTP12.032.CThe WWOX gene variants detection in patient with cerebellar ataxia using optical genome mappingRutkowska K.June 3, 202410:15-11:15 AM CESTP01.051.CEnhanced cytogenomic analysis of complex karyotype in myelodysplastic syndrome using optical genome mappingValkama A.June 3, 202410:15-11:15 AM CESTP21.065.DAdvancing genetic diagnostics: optical genome mapping’s efficacy in identifying structural variants for autosomal recessive diseasesBeyza Ogutlu O.June 3, 202416:45-17:45 PM CESTP15.079.DBenefits of the analysis of a complex chromosomal rearrangement in the implementation of long read approachesChambon P.June 3, 202416:45-17:45 PM CESTP04.011.DA combined approach of innovative DNA- and RNA-technologies reveals hidden LINE-1/ERV insertion in IQCB1 as causative variant for Senior Løken syndromede Bruijn S.June 3, 202416:45-17:45 PM CESTP01.056.DExome sequencing identified rare recurrent copy number variants and hereditary breast cancer susceptibilityMantere T.June 3, 202416:45-17:45 PM CESTP15.091.DA multimodal approach to molecular diagnosis in NF1 highlights the need for bespoke analysis in undiagnosed patientsMcAleese-Park E.June 3, 202416:45-17:45 PM CESTP10.021.DOptical genome mapping finally unveils the genetic cause of aniridia and intellectual disability in a 17-year-old after seven years of diagnostic odysseyTelman W.June 3, 202416:45-17:45 PM CESTE-posterOptical genome mapping for comprehensive genomic rearrangement analysisFlunkert J.OnlineE-posterOptical genome mapping: lighting the way in complex clinical casesMonge Lobo I.OnlineE-posterRefining genotype-phenotype correlation in complex chromosomal rearrangements using optical genome mapping – case reportVallova V.OnlineE-posterUnraveling the mysteries of balanced rearrangements: optical genome mapping spotlights BCL11B misregulation in a familial translocationAlcalá San Martín A.OnlineE-posterOptical genome mapping (OGM) allows the characterization of a complex chromosome rearrangement associated with recurrent pregnancy lossTrost D.OnlineE-posterFocus on deletions and duplications identified by optical genome mapping technique in a cohort of 100 patients: comparison with MCADoco-Fenzy M.OnlineRoomTitlePresenterPresentedPoster presentationOptical genome mapping identifies hidden structural variants in previously undiagnosed rare disease cases in Solve-RDvan der Sanden B.June 1, 202419:00-19:15 PM CEST, Room A8Poster presentationMultiomics and deep phenotyping in MECP2 Duplication syndrome: insight into disease severity, expression variability, and nucleic acid therapeuticsPehlivan D.June 1, 202419:45-20:00 PM CEST, Room A8Poster presentationNext generation cytogenetics by optical genome mappingKanagal-Shamanna R.June 3, 202408:30-10:00 AM CEST, Room A2Sponsored sessionInsights into constitutional disorders and beyond: scaling to new heights with optical genome mappingChaubey A., Batlle Masó L., van der Sanden B., Ek M.June 3, 202414:00-15:30 PM CESTRoom New York 3 (Level 1) ACC scientific presentations and poster sessions: Scientific presentations and poster sessions on OGM at ACC take place in the exhibition hall. Poster/PresentationTitlePresenterPresentedExhibitor theater sessionRevolutionizing cytogenomics with optical genome mapping: high-resolution structural variant detection with an elevated sample-to-answer workflowGallagher M.June 3, 202412:15-12:35 PM ESTPoster presentationEnhanced detection of primary oncogenic drivers in pediatric T-lymphoblastic leukemia (T-ALL) by optical genome mapping (OGM)Raca G.June 3, 20242:00-2:15 PM ESTPoster presentationUtility of optical genome mapping as an additional tool to standard cytogenetic workup in hematological malignanciesToruner G.June 3, 20242:15-2:30 PM ESTPoster presentationA curated research catalogue of structural variation from 809 postnatal cases detected by optical genome mappingPang A.June 3, 20244:00-4:15 PM ESTPoster presentationA search for genetic determinants in neural tube defects using optical genome mappingSahajpal N.June 3, 20244:15-4:30 PM ESTPoster presentationCross-comparison of optical genome mapping and chromosomal microarray data using VIA softwareYu J.June 3, 20244:30-4:45 PM ESTPoster hallEfficient hematological malignancy analysis and reporting workflow using optical genome mappingClifford B. Poster hallIsotachophoresis (ITP) for high-throughput isolation of UHMW gDNA suitable for optical genome mapping (OGM)Yadav M. More details on Bionano’s presence at the ESHG conference can be found here, and virtual posters will be shown here; more details on Bionano’s presence at the ACC conference can be found here. About Bionano Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. The Company also offers an industry-leading, platform-agnostic genome analysis software solution and nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also offers OGM-based diagnostic testing services. For more information, visit www.bionano.com, www.bionanolaboratories.com or www.purigenbio.com. Unless specifically noted otherwise, Bionano’s OGM products are for research use only and not for use in diagnostic procedures. Forward-Looking Statements of Bionano This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “ability,” “believe,” “may,” “potential,” “will,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, OGM’s utility for genetic disorder, rare disease, and cancer research applications; OGM’s ability and utility for resolving HAE cases; the ability and utility of OGM to detect SVs relevant to rare disease; the ability of OGM to unveil more cytogenomic insights into multiple myeloma samples than traditional cytogenetic methods; OGM’s ability to enhance detection of pathogenic variants and to advance genetic disease research; the utility of the latest innovations in OGM workflows, including the Stratys system and VIA software; the utility of OGM for research in the areas reported in the presentations given and the posters made available at the ESHG Annual Conference 2024 and AAC 2024; the growth and adoption of OGM for use in genetic disorder, rare disease, and cancer research applications; the ability and utility of our OGM solutions to drive market adoption of OGM; and any other statements not of historical fact. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: global and macroeconomic events, such as the impact of the global pandemics, bank failures, interest rate changes, supply disruptions, and the ongoing conflicts in the Ukraine and Russia and between Israel and Hamas, and related sanctions, on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive technologies or improvements to existing technologies; the failure of OGM’s utility for genetic disorder, rare disease, and cancer research applications; the failure of OGM to resolve HAE cases; the failure of OGM to detect SVs relevant to rare disease; the failure of OGM to unveil more cytogenomic insights into multiple myeloma samples than traditional cytogenetic methods; the failure of OGM to enhance detection of pathogenic variants and to advance genetic disease research; the failure of our latest innovations in OGM workflows, including the Stratys system and VIA software; the failure of OGM for research in the areas reported in the presentations given and the posters made available at the ESHG Annual Conference 2024 and AAC 2024; the growth and adoption of OGM for use in genetic disorder, rare disease, and cancer research applications; the ability and utility of our OGM solutions to drive market adoption of OGM; the ability of our OGM solutions to offer the anticipated benefits for and contributions to the areas reported in the presentations given and posters made available at the ESHG Annual Conference 2024 and AAC 2024; future study results contradicting the results reported in the presentations given and posters made available at the ESHG Annual Conference 2024 and AAC 2024; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts and to continue as a "going concern”; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2023 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise. CONTACTS Company Contact:Erik Holmlin, CEOBionano Genomics, Inc.+1 (858) 888-7610eholmlin@bionano.com Investor Relations:David HolmesGilmartin Group+1 (858) 888-7625IR@bionano.com

NeoPhore is developing a pipeline of drugs targeting proteins along the DNA mismatch repair (MMR) pathway. Image credit: Shutterstock/Billion Photos. NeoPhore has raised £9.6m ($12.2m) in a Series B financing extension, bringing the round’s total to £31.1m. Sixth Element Capital, which is currently managing the CRT Pioneer Fund (CPF), led the round, with participation from existing backers and three new investors, as per a 1 February press release. The UK-based company, which spun out of the University of Turin and the UK-based PhoreMost, extended the round with a £6m extension in January 2023. The CPF is a joint initiative between Cancer Research Technology (CRT) and the European Investment Fund (EIF). NeoPhore is developing a pipeline of drugs targeting proteins along the DNA mismatch repair (MMR) pathway. MMR deficiency is where errors in DNA base pairing are not corrected. Cells that do not have these routine corrections can have many mutations, which could lead to cancer. NeoPhore says that this tumour suppressor pathway is lost in up to 40% of sporadic cancers. The company announced its lead compound, NP1867, which targets the MMR protein PMS2, at AACR-NCI-EORTC, held in Boston, US, from 7 to 10 October 2023. NeoPhore said the funding would help advance its lead oral programme. See Also: Gilead and Arcus Biosciences expand oncology partnership deal Synnovation launches with $102m to advance therapy pipeline The UK-based biotech is homing in on raising tumour mutational burdens. Deficient MMR can result in a high-frequency microsatellite instability MSI (MSI-H) phenotype. Higher MSI status is linked with the creation of neoantigens – substrates that help mediate immune activation. Neoantigens are already being explored in cancer vaccines, such as BioNTech ’s highly anticipated RNA vaccine for pancreatic cancer. NeoPhore is developing small molecule MMR inhibitors that induce neoantigen expression intending to increase immunogenicity in solid tumours. This would make cancer patients more responsive to immunotherapy. NeoPhore says that the combination of immune checkpoint inhibitors such as PD-1 inhibitors, together with an increased neoantigen repertoire could elicit more efficacious tumour treatment. MSD’s blockbuster Keytruda is the best-selling PD-1 inhibitor, and one of the top-selling drugs worldwide – generating $20.9bn in sales in 2022. The drug is approved for patients with unresectable or metastatic MSI-H or MMR-deficient solid tumours, amongst others. NeoPhore’s CEO Dr Matthew Baker said: “With the support of our committed and new investors, along with our research collaborations with academic institutions that are in place, we remain on track to deliver a candidate drug for our lead PMS2 program by early 2025.”

- Sponsor of the Heart of Genetic Counseling program and award, recognizing excellence in patient care - - These studies combined with new digital tools aim to increase access and frequency of hereditary cancer screening both before and during treatment - SAN FRANCISCO, Oct. 10, 2023 /PRNewswire/ -- Researchers from Invitae (NYSE: NVTA), a leading medical genetics company, are showcasing their work next week at the National Society of Genetic Counselors (NSGC) 42nd Annual Conference in Chicago that highlights the importance of genetics-informed patient care. In addition to its research presentations, the company will present the Heart of Genetic Counseling Award which recognizes excellence in the field of genetic counseling. The company's research presentations, which include a sponsored session, oral presentations and posters, present data on improvements in classifying Variants of Uncertain Significance (VUS), how using digital tools can increase hereditary cancer screening access and other topics related to the field of medical genomics. The sponsored session will focus on the ever-evolving field of genetic counseling and the tools needed to navigate change through an interactive workshop using the odyssey planning framework. "The NSGC Annual Conference is a great opportunity for Invitae researchers to share cutting-edge scientific advancements with genetic counselors who play an integral role in genetics-informed patient care," said Robert Nussbaum, M.D., chief medical officer at Invitae. "It also gives us a chance to show our continued commitment to genetic counselors and their patients by awarding the Heart of Genetic Counseling Award to a genetic counselor who was nominated by a patient for extraordinary care and compassion." Heart of Genetic Counseling Award Invitae joins NSGC in presenting the Heart of Genetic Counseling Award – honoring excellence in genetic counseling and patient care as recognized by patients. The nominations include patient stories that highlight the significant clinical and personal impact their genetic counselor had on their lives and the lives of their families. This year's award will be presented during the ceremony on Wednesday, October 18, at 7 p.m. CT. Among several nominations, the finalists are: Leslie Walsh Cyprych MS, MPH, CGC, Children's Hospital of Pittsburgh, was nominated by a mother for providing unwavering patient advocacy, support and compassion after her daughter was diagnosed with Aicardi-Goutieres syndrome (AGS), a rare, progressive, and incurable genetic disease. Cyprych has continuously gone above and beyond to coordinate the daughter's care, help navigate the healthcare system, and to provide information and meaningful emotional support. Andrea Gainey MS, LCGC, UConn Health Huntington's Disease Program, provided crucial care, comfort and guidance to a family facing Huntington's Disease (HD). Gainey understands the stigma that surrounds HD and how difficult the decision to test is and helped establish free anonymous testing and confidential lab reports. Considered a leader in the HD community, Gainey has helped generations of families deal with this devastating disease on a daily basis. Victoria Suslovitch MS, CGC, Ambry Genetics, formerly with Boston Children's Hospital, was nominated for offering compassion, emotional support and guidance to a family whose son is affected by a devastating rare genetic disease, called KCNQ2 developmental epileptic encephalopathy. Suslovitch was a guiding light helping each family member deal with their frightening medical journey. Suslovitch drew on her personal experience to connect with siblings as both a peer and professional and taught healthy coping mechanisms. The Heart of Genetic Counseling Award will be presented on Wednesday, October 18, from 7 p.m. to 9 p.m. CT. Full presentation schedule Invitae continues to demonstrate scientific innovation and excellence as supported by the number of accepted sessions, presentations, and posters. The full schedule of Invitae presentations and posters at the conference can be found on our website. Wednesday, October 18 Poster CAN65. Cascade testing with comprehensive multigene panels for hereditary cancer identifies unexpected findings in relatives. | Presented by: Brandie Heald, M.S., C.G.C., Invitae. | 5:30 p.m. – 7 p.m. CT Poster CAN75. One of these is not like the others: a descriptive study of the attenuated phenotype of PMS2 | Presented by: Brandie Heald, M.S., C.G.C., Invitae. | 5:30 p.m – 7 p.m. CT Poster CAN67. Patient uptake of physician recommendations following prostate cancer germline genetic testing. | Presented by: Sarah M. Nielsen, Invitae. | 5:30 p.m. – 7 p.m. CT Heart of Genetic Counseling Award Presentation | Presented by: Invitae and NSGC. | 7 p.m. – 9 p.m. CT Thursday, October 19 Educational Breakout Session C03. Increasing access to hereditary cancer screening: emerging evidence on the use of digital tools for ascertainment of individuals at risk and considerations for care delivery. | Presented by: Shivani Nazareth, M.S., C.G.C., Wendy Kohlmann, M.S., C.G.C., Vera Cherepakho, L.C.G.C., Meredith Gerhart, M.S., C.G.C., Sarah Knerr, Ph.D., Catharine Wang, Ph.D., Rebecca Carr, M.S., C.G.C., Colleen Caleshu, M.S., C.G.C., Sarah Savage, M.S., C.G.C. | 11 a.m. – 12:30 p.m. CT Sponsored session. Charting your genetic counseling odyssey: Navigating with purpose and vision. | Presented by: Jennifer Young, Ph.D., Feinberg School of Medicine Northwestern University, and Ana Morales, M.S., C.G.C., Invitae. | 12:45 p.m. – 2 p.m. CT Poster CAN64. The estimated healthcare spend to identify one hereditary cancer syndrome patient with a deep intronic pathogenic variant by RNA sequencing is nearly 500x more costly than identifying one patient with multi-gene panel DNA testing. | Presented by: Brandie Heald, M.S., C.G.C., Invitae. | 4:30 p.m. – 6:30 p.m. CT Poster GGT218. Minimizing uncertainty and increasing equity in genetic testing: the role of machine learning tools in the classification of genetic variants. | Presented by: Flavia M. Facio, M.S., C.G.C.. Invitae. | 4:30 p.m. – 6:30 p.m. CT Poster GGT282: Utilization of an Automated, Probability-Based Algorithm to Determine Pharmacogenomic Adverse Drug Outcome Risk in Cancer Patients. | Presented by: Sienna Aguilar, M.S., L.C.G.C., Invitae. | 4:30-6:30 p.m. Poster GGT256. Positive yield of reproductive carrier screening in the context of revised ACMG recommendations for tiered carrier screening. | Presented by: Dana Neitzel, M.S., C.G.C., Invitae. | 4:30-6:30 p.m. CT Oral Presentation B16. User Testing of a Pre-Visit Chatbot Developed for Population Genomic Screening and Counseling. | Presented by: Kelly Morgan, M.S., C.G.C. | 4:45-5:45 p.m. CT Oral Presentation B17. Yield of integrated DNA and RNA analysis of hereditary cancer associated genes based on cancer diagnosis. | Presented by: Brandie Heald, M.S., C.G.C., Invitae. | 4:45 - 5:45 p.m. CT Friday, October 20 Oral Presentation C14. A Pilot Study Comparing the Effectiveness of Pre-test Genetic Counseling Using a Chatbot versus Traditional In-person Genetic Counseling in Women Newly Diagnosed with Breast Cancer. | Presented by: Ryan Noss, M.S., C.G.C. | 10:15 a.m. - 11:15 a.m. CT On-demand session Advancing Variant Classification: Steps in Reducing Uncertainty and Improving Patient Outcomes. | Presented by: Heidi Rehm, Ph.D., Yuya Kobayashi, Ph.D., Jason Carmichael, M.S., C.G.C., Sayoni Lahiri, C.G.C., Flavia M. Facio C.G.C. | Available in the live stream and on-demand portions of the program via NSGC conference app. To learn more about Invitae's presence at the NSGC 42nd Annual Conference or the Heart of Genetic Counseling Award, visit our website. About Invitae Invitae (NYSE: NVTA) is a leading medical genetics company trusted by millions of patients and their providers to deliver timely genetic information using digital technology. We aim to provide accurate and actionable answers to strengthen medical decision-making for individuals and their families. Invitae's genetics experts apply a rigorous approach to data and research, serving as the foundation of their mission to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. To learn more, visit invitae.com and follow for updates on Twitter, Instagram, Facebook and LinkedIn @Invitae. Safe Harbor Statement This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the content of the company's research presentations and posters; the objectives of the company's studies and tools; and the company's beliefs regarding the quality and impact of its research. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the company's ability to grow its business in a cost-efficient manner; the company's history of losses; the company's ability to maintain important customer relationships; the company's ability to compete; the company's need to scale its infrastructure in advance of demand for its tests and to increase demand for its tests; the risk that the company may not obtain or maintain sufficient levels of reimbursement for its tests; the applicability of clinical results to actual outcomes; the company's ability to use rapidly changing genetic data to interpret test results accurately and consistently; risks associated with litigation; security breaches, loss of data and other disruptions; laws and regulations applicable to the company's business; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2023. These forward-looking statements speak only as of the date hereof, and Invitae Corporation disclaims any obligation to update these forward-looking statements. Contact: Amanda McQuery [email protected] (628) 213-3283 SOURCE Invitae Corporation